Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 40

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 includes facility expenses, office supplies, computer related costs, public relations costs, recruiting costs and conferences.

•Stock-based Compensation relates to stock options granted to our employees and board members and warrants granted to our independent consultants who work in the general and administrative aspects.

Other income and expenses

We earned interest income on our cash balances and investments in U.S. Treasury bills.

17

Results of Operations

The following tables summarize our results of operations for the three and six months ended June 30, 2025 and 2024 (in thousands):

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeOperating expenses:Research and development$1,541 $3,563 $(2,022)$3,730 $6,378 $(2,648)General and administrative1,164 1,506 (342)2,369 3,434 (1,065)Total operating expenses2,705 5,069 (2,364)6,099 9,812 (3,713)Loss from operations(2,705)(5,069)2,364 (6,099)(9,812)3,713 Interest income17 98 (81)33 238 (205)Other income, net151 - 151 182 - 182 Net loss$(2,537)$(4,971)$2,434 $(5,884)$(9,574)$3,690 

Three Months Ended June 30,Six Months Ended June 30,20252024Change20252024ChangeResearch and development expenses:Clinical trial expenses:IT-01 Study (Phase 1/2 Metastatic Cancers)$— $7 $(7)$— $61 $(61)INVINCIBLE-2 Study (Phase 2 Breast)— 117 (117)— 221 (221)INVINCIBLE-3 Study (Phase 3 Sarcoma)788 1,970 (1,182)2,383 3,388 (1,005)INVINCIBLE-4 Study (Phase 2 Breast)134 315 (181)197 315 (118)Other14 58 (44)14 58 (44)Clinical trial expenses936 2,467 (1,531)2,594 4,043 (1,449)Contract manufacturing